F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice

被引:0
|
作者
Marie-Bernadette Assié
Laurent Bardin
Agnès Auclair
Nathalie Consul-Denjean
François Sautel
Ronan Depoortère
Adrian Newman-Tancredi
机构
[1] Centre de Recherche Pierre Fabre,
关键词
Antipsychotic; Mouse brain; F15063; Plasma levels; Apomorphine-induced climbing and sniffing; D2-like receptor occupancy;
D O I
暂无
中图分类号
学科分类号
摘要
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine fumarate salt) is a novel potential antipsychotic with dopamine D2/D3 blocking properties and agonist activity at 5-HT1A and D4 receptors. The pertinent parameter for pharmacological activity of antipsychotics appears to be central D2-like receptor occupancy. However, its duration is not necessarily correlated with drug plasma levels, on which clinical dosing regimens are often based. Thus, we compared in mice the duration of actions of F15063 and haloperidol to (1) inhibit apomorphine-induced climbing and sniffing (behavioural measures of D2-like receptor antagonism) and (2) occupy D2-like receptors in vivo in the striatum and olfactory tubercles (inhibition of [3H]nemonapride binding). Finally, we measured plasma levels of F15063. D2-like receptor occupancy in the striatum remained elevated at 1, 4 and 8 h postadministration, with both F15063 (ID50: 7.1, 3.6 and 16.5 mg/kg p.o., respectively) and the typical antipsychotic, haloperidol (ID50: 1.4, 0.52 and 0.53 mg/kg p.o., respectively). This was paralleled by a protracted inhibition of apomorphine-induced climbing (ED50: 0.9, 2.8 and 3.6 mg/kg p.o., and 0.21, 0.37 and 0.87 mg/kg p.o., respectively, for F15063 and haloperidol). In contrast, after administration of 10 mg/kg p.o. of F15063, its plasma levels decreased rapidly: 15.2, 2.1 and 0.6 ng/ml, 1, 4 and 8 h after administration, respectively. A similar pattern of results was observed when F15063 and haloperidol were administered i.p. and s.c., respectively. To summarise, the time-course of D2-like receptor occupancy and inhibition of apomorphine-climbing (and sniffing) behaviours was similarly long lasting with F15063 and haloperidol. In addition, the durations of action of F15063 and haloperidol in a behavioural model of antipsychotic-like activity were closely correlated to their occupancy of central D2-like receptors, and much longer than their presence in plasma.
引用
收藏
页码:241 / 250
页数:9
相关论文
共 50 条
  • [41] Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects
    Meszaros, G. Pasztor
    Kapas, M.
    Borsos, M.
    Laszlovszky, I.
    Nemeth, G.
    Tihanyi, K.
    Szombathelyi, Z.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S451 - S452
  • [42] Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
    Kiss, Bela
    Horvath, Attila
    Nemethy, Zsolt
    Schmidt, Eva
    Laszlovszky, Istvan
    Bugovics, Gyula
    Fazekas, Karoly
    Hornok, Katalin
    Orosz, Szabolcs
    Gyertyan, Istvan
    Agai-Csongor, Eva
    Domany, Gyoergy
    Tihanyi, Karoly
    Adham, Nika
    Szombathelyi, Zsolt
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 333 (01): : 328 - 340
  • [43] The selective dopamine D4 receptor antagonist L-745,870 produces antipsychotic-like effects in the presence of a weak dopamine D2 receptor blockade in rats
    Wadenberg, ML
    Elia, Y
    NORDIC JOURNAL OF PSYCHIATRY, 2001, 55 (02) : 104 - 104
  • [44] Effects of pardoprunox (SLV308), a partial D2/D3 receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity
    Betry, C.
    Etievant, A.
    Lambas-Senas, L.
    McCreary, A.
    Haddjeri, N.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S117 - S117
  • [45] CARIPRAZINE, A D3-PREFERRING DOPAMINE D3/D2 RECEPTOR PARTIAL AGONIST ANTIPSYCHOTIC CANDIDATE DEMONSTRATES ANTI-ABUSE POTENTIAL IN RATS
    Gyertyan, Istvan
    Roman, V.
    Saghy, K.
    Kiss, B.
    Szombathelyi, Z.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 288 - 289
  • [46] SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist.: II:: Behavioral profile predictive of an atypical antipsychotic activity
    Depoortere, R
    Boulay, D
    Perrault, G
    Bergis, O
    Decobert, M
    Françon, D
    Jung, M
    Simiand, J
    Soubrié, P
    Scatton, B
    NEUROPSYCHOPHARMACOLOGY, 2003, 28 (11) : 1889 - 1902
  • [47] SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity
    Ronan Depoortere
    Denis Boulay
    Ghislaine Perrault
    Olivier Bergis
    Michel Decobert
    Dominique Françon
    Mireille Jung
    Jacques Simiand
    Philippe Soubrié
    Bernard Scatton
    Neuropsychopharmacology, 2003, 28 : 1889 - 1902
  • [48] RGH-188, a D3/D2 dopamine receptor partial agonist antipsychotic candidate with excellent brain availability and low EPS liability
    Gyertyan, Istvan
    Kiss, Bela
    Saghy, Katalin
    Pasztor, Gabriella
    Gemesi, Larisza I.
    Kapas, Margit
    Agai-Csongor, Eva
    Domany, Gyorgy
    Tihanyi, Karoly
    Szombathelyi, Zsolt
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 76S - 76S
  • [49] In Vivo Effects of Pardoprunox (SLV308), a Partial D2/D3 Receptor and 5-HT1A Receptor Agonist, on Rat Dopamine and Serotonin Neuronal Activity
    Betry, Cecile
    Etievant, Adeline
    Lambas-Senas, Laura
    Mccreary, Andrew C.
    Haddjeri, Nasser
    SYNAPSE, 2011, 65 (10) : 1042 - 1051
  • [50] RGH-188, potential antipsychotic with D3/D2 antagonist/partial agonist properties, exhibits an atypical antipsychotic profile in rats with respect to effect oil spontaneously active dopamine neurons
    Adham-Parangi, N.
    Kiss, B.
    Gyertyan, I.
    Gupta, S.
    Szombathelyi, Z.
    Ashby, C.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 263 - 263